NLM Selects InTouch for Indexing in the MEDLARS System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

WASHINGTON-InTouch magazine, published by PRR for cancer patients and their family members, has been selected by the US National Library of Medicine (NLM) to be indexed and included in Index Medicus and MEDLINE.

WASHINGTON—InTouch magazine, published by PRR for cancer patients and their family members, has been selected by the US National Library of Medicine (NLM) to be indexed and included in Index Medicus and MEDLINE.

"It’s a real tribute to the editorial quality of InTouch," Steven T. Rosen, MD, said. Dr. Rosen, director of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, serves as medical editor-in-chief for InTouch, which just celebrated its third year of publication.

The National Library of Medicine looks to an advisory committee—the Literature Selection Technical Review Committee—to choose journals and other publications for citation. Composed of authorities knowledgeable in the field of biomedicine, the committee includes physicians, researchers, educators, editors, health science librarians, and historians who review and recommend titles for indexing.

The databases in the MEDLARS system in which InTouch will appear are Index Medicus and its online counterpart, MEDLINE, the system’s principal online bibliographic citation database. About 4,500 titles are indexed and included in the MEDLINE database, and 3,630 in Index Medicus.

"We’re delighted that the NLM has recognized the integrity and value of the information in InTouch," Dr. Rosen said. "Their endorsement furthers our mission, which is to give patients and their loved ones the most authoritative and up-to-date information on cancer prevention and treatment so that they can be better informed about their health care."

To search MEDLINE, go to PubMed located on the web at www.ncbi.nih.gov/entrez/query.fcgi.  

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content